Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia

The aim of this study was to investigate the relationship between the functional C957T single-nucleotide polymorphism of the dopamine D2 receptor (DRD2) gene and the risk for schizophrenia. We therefore conducted a case-control association study of 188 Finnish schizophrenia patients meeting the DSM-IV criteria and 384 healthy controls. The 5' nuclease assay (TaqMan) was used to determine genotypes. A greater proportion of patients with schizophrenia than healthy controls were C-allele carriers (odds ratio 1.5, 95% confidence interval (CI) 1.0-2.3, P=0.05). Our results are in agreement with an earlier association study suggesting that the C957T C-allele plays a role in the genetic vulnerability for schizophrenia and support the involvement of the DRD2 gene in schizophrenia pathogenesis.

[1]  P. McGuffin,et al.  Genetic basis of schizophrenia , 1995, The Lancet.

[2]  M. Laruelle.  Dopamine Transmission in the Schizophrenic Brain , 2007 .

[3]  J. Lieberman,et al.  Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations , 2005, Psychopharmacology.

[4]  Laurent Gouya,et al.  The 3′ region of the DRD2 gene is involved in genetic susceptibility to schizophrenia , 2004, Schizophrenia Research.

[5]  T. Lappalainen,et al.  Regional differences among the Finns: a Y-chromosomal perspective. , 2006, Gene.

[6]  R. V. Van Heertum,et al.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  N. Saitou,et al.  Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. , 2003, Human molecular genetics.

[8]  J. Lieberman,et al.  Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs , 2005, Molecular Psychiatry.

[9]  K. Livak,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay. , 1999, Genetic analysis : biomolecular engineering.

[10]  T Foitzi,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay , 1999 .

[11]  P. Gorwood,et al.  Association and excess of transmission of a DRD2 haplotype in a sample of French schizophrenic patients. , 2001, Schizophrenia Research.

[12]  S. Faraone,et al.  The Genetic Basis of Schizophrenia , 2004 .

[13]  P. Sullivan,et al.  Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. , 2003, Archives of general psychiatry.

[14]  K. Någren,et al.  C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo , 2004, Molecular Psychiatry.

[15]  J. Lieberman.  Dopamine Partial Agonists , 2004, CNS drugs.

[16]  C. P. Morris,et al.  The C/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia , 2005, Schizophrenia Research.